• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.15% Nasdaq Up0.36%

    IntelliPharmaCeutics International Inc. (IPCI)

    -NasdaqCM
    2.32 Down 0.08(3.33%) Dec 19, 4:00PM EST
    Add to Portfolio
    ProfileGet Profile for:
    IntelliPharmaCeutics International Inc.
    30 Worcester Road
    Toronto, ON M9W 5X2
    Canada - Map
    Phone: 416-798-3001
    Fax: 416-798-3007
    Website: http://www.intellipharmaceutics.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Drug Delivery
    Full Time Employees:38

    Business Summary 

    Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled and targeted release oral solid dosage drugs in Canada. The company has a pipeline of products based on its patented Hypermatrix technology in various stages of development in therapeutic areas, such as neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. Its products under FDA review include Focalin XR, an extended release capsule for hyperactivity disorders; Effexor XR, an extended release capsule for depression; Protonix, a tablet for gastroesophageal reflux diseases; Glucophage XR, a tablet for managing type 2 diabetes; Seroquel XR, a tablet for the treatment of schizophrenia, bipolar disorders, and depressive disorders; Lamictal XR, a tablet for anti-convulsant for epilepsy; and Keppra XR, a tablet for the treatment of partial onset seizures for epilepsy, as well as Pristiq, a tablet for depression. The company is also developing Coreg CR, a capsule, which is in late-stage development for heart failure and hypertension; OxyContin, a controlled release capsule that is in phase I clinical trial for pain; and Lyrica, a capsule, which is in phase I clinical trial for neuropathic pain. Its non-generic products under development include Rexista, an oral formulation for pain relief; and Regabati XR, a pregabalin extended release capsule that has completed an initial phase I clinical trial for neuropathic pain. The company has a license and commercialization agreement with Par Pharmaceutical, Inc. for the development and commercialization of generic Focalin XR. Intellipharmaceutics International Inc. is headquartered in Toronto, Canada.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on IntelliPharmaCeutics International Inc.

    Key Executives 
     PayExercised
    Dr. Isa Odidi Ph.D., MBA, 56
    Co-Founder, Chairman, Chairman of Scientific Advisory Board, Chief Exec. Officer and Co-Chief Scientific Officer
    521.00K0.00
    Dr. Amina Odidi Ph.D., 54
    Pres, Chief Operating Officer, Principal Accounting Officer, Co-Chief Scientific Officer and Director
    521.00K0.00
    Mr. John Newell Allport B.A.Sc., M.A., LL.B., 68
    VP of Legal Affairs & Licensing, Sec., Director and Member of Corp. Governance Committee
    153.00K0.00
    Mr. Domenic Della Penna ,
    Chief Financial Officer
    N/AN/A
    Mr. Glenn Neumann ,
    Director of Investor Relations
    N/AN/A
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.